[HTML][HTML] Interferons—Implications in the Immune Response to Respiratory Viruses

HC Bergeron, MR Hansen, RA Tripp - Microorganisms, 2023 - mdpi.com
Interferons (IFN) are an assemblage of signaling proteins made and released by various host
cells in response to stimuli, including viruses. Respiratory syncytial virus (RSV), influenza …

Stellate ganglion block for the treatment of hot flashes in patients with breast cancer: a literature review

…, J Abdelmalak, E Jusino, MR Hansen… - Ochsner …, 2015 - ochsnerjournal.org
Background Currently, hormone replacement therapy (HRT) is the only US Food and Drug
Administration-approved treatment for hot flashes, resulting in clinical improvement in 80%-90…

Effect of a sports food bar on fat utilisation and exercise duration

…, JN MacTaggart, MR Hansen - Canadian journal of …, 1998 - cdnsciencepub.com
The manufacturer claims that using the Access Fat Conversion Activity Bar increases fat
utilisation, which would have a glycogen-sparing effect and delay the onset of fatigue from …

Facile one-step synthesis of palladium tellurium alloy nanorods

K Mariappan, SJP Varapragasam, MR Hansen… - Journal of …, 2018 - Elsevier
A palladium-tellurium binary alloy nanomaterial was synthesized by a one-pot reaction of bis(4-methoxyphenyltelluro)methane
[(4-CH 3 OC 6 H 4 Te) 2 CH 2 ](1) and allylpalladium (II)…

[PDF][PDF] Targeting KRAS mutant cancers with a covalent G12C-specific inhibitor

MR Janes, J Zhang, LS Li, R Hansen, U Peters, X Guo… - Cell, 2018 - cell.com
KRAS G12C was recently identified to be potentially druggable by allele-specific covalent
targeting of Cys-12 in vicinity to an inducible allosteric switch II pocket (S-IIP). Success of this …

Selective inhibition of oncogenic KRAS output with small molecules targeting the inactive state

MP Patricelli, MR Janes, LS Li, R Hansen, U Peters… - Cancer discovery, 2016 - AACR
KRAS gain-of-function mutations occur in approximately 30% of all human cancers. Despite
more than 30 years of KRAS-focused research and development efforts, no targeted therapy …

The reactivity-driven biochemical mechanism of covalent KRASG12C inhibitors

R Hansen, U Peters, A Babbar, Y Chen… - Nature structural & …, 2018 - nature.com
Activating mutations in KRAS are among the most common tumor driver mutations. Until
recently, KRAS had been considered undruggable with small molecules; the discovery of the …

Comparative genomics of Campylobacter concisus: Analysis of clinical strains reveals genome diversity and pathogenic potential

…, S Berry, I Mukhopadhya, R Hansen… - Emerging microbes & …, 2018 - Taylor & Francis
In recent years, an increasing number of Campylobacter species have been associated with
human gastrointestinal (GI) diseases including gastroenteritis, inflammatory bowel disease, …

Production and use of calcined natural pozzolans in concrete

GS Barger, ER Hansen… - Cement …, 2001 - asmedigitalcollection.asme.org
The goal of producing concrete that provides longterm durability with regard to properties
such as improved sulfate resistance and reduced susceptibility to alkali-silica reactions (ASR) …

[HTML][HTML] An internally controlled quantitative target occupancy assay for covalent inhibitors

R Hansen, SJ Firdaus, S Li, MR Janes, J Zhang… - Scientific Reports, 2018 - nature.com
Assessing target occupancy is critical for establishing proof-of-mechanism for novel inhibitors
and to determine whether robust target inhibition can be achieved at tolerated doses. This …